{"id":1102,"date":"2009-02-09T22:41:43","date_gmt":"2009-02-09T22:41:43","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=1102"},"modified":"2013-08-16T15:06:43","modified_gmt":"2013-08-16T15:06:43","slug":"recent-reports-on-new-drug-interactions","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/1102","title":{"rendered":"Elvitegravir with tipranavir\/ritonavir or darunavir\/ritonavir"},"content":{"rendered":"<p><strong><a href=\"http:\/\/www.hiv-druginteractions.org\/\">http:\/\/www.hiv-druginteractions.org<\/a><\/strong><\/p>\n<p><strong>Two studies are described evaluating potential pharmacokinetic interactions among elvitegravir and ritonavir-boosted tipranavir or darunavir.<\/strong><\/p>\n<p>In the tipranavir study healthy volunteers received elvitegravir\/ritonavir (200\/100 mg once daily) alone, or tipranavir\/ritonavir (500\/200 mg twice daily) alone, or elvitegravir (200 mg once daily) in combination with tipranavir\/ritonavir (500\/200 mg twice daily). For the darunavir study subjects received elvitegravir\/ritonavir (125\/100 mg once daily) alone, or darunavir \/ritonavir (600\/100 mg twice daily) alone, or elvitegravir (125 mg once daily) in combination with darunavir \/ritonavir (600\/100 mg twice daily). Steady state pharmacokinetics for elvitegravir, tipranavir, darunavir and ritonavir were determined.<\/p>\n<p>No subjects discontinued for adverse events during treatment with elvitegravir\/ritonavir alone. On coadministration, AUC and Cmax of elvitegravir\/tipranavir and elvitegravir\/darunavir were within respecified no-effect boundaries versus treatment alone; trough concentrations were also not substantially altered. The authors concluded that elvitegravir can be added to tipranavir\/ritonavir or darunavir\/ritonavir regimens without dose adjustment.<\/p>\n<p>Reference:<\/p>\n<p>Mathias AA et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr, 2008, 49(2): 156-162.<a href=\"http:\/\/www.hiv-druginteractions.org\/frames.asp?new\/Content.asp?ID=405\"><br \/>\nhttp:\/\/www.hiv-druginteractions.org\/frames.asp?new\/Content.asp?ID=405<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>http:\/\/www.hiv-druginteractions.org Two studies are described evaluating potential pharmacokinetic interactions among elvitegravir and ritonavir-boosted tipranavir or darunavir. In the tipranavir study healthy volunteers received elvitegravir\/ritonavir (200\/100 mg once daily) alone, or tipranavir\/ritonavir (500\/200 mg twice daily) alone, or elvitegravir (200 mg &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-1102","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=1102"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1102\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=1102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=1102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=1102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}